{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:29:47Z","timestamp":1792178987058,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Initiative f\u00fcr das rheumakranke Kind"},{"name":"u can ride 4 arthritis"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12969-018-0257-6","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T07:56:53Z","timestamp":1529913413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9247-4729","authenticated-orcid":false,"given":"Claas H.","family":"Hinze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad T.","family":"Oommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weller-Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Speth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Lainka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Fesq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"M\u00fcller-Felber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Neudorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rietschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes-Peter","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"issue":"9631","key":"257_CR1","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","volume":"371","author":"BM Feldman","year":"2008","unstructured":"Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201\u201312.","journal-title":"Lancet"},{"issue":"8","key":"257_CR2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/rheumatology\/kel025","volume":"45","author":"VE Brown","year":"2006","unstructured":"Brown VE, Pilkington CA, Feldman BM, Davidson JE, Network for Juvenile Dermatomyositis PRES. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45(8):990\u20133.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"257_CR3","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3899\/jrheum.090953","volume":"37","author":"E Stringer","year":"2010","unstructured":"Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, Lindsley CB, Ota S, Pilkington C, Reed AM, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: the childhood arthritis and rheumatology research alliance (CARRA) JDM treatment survey. J Rheumatol. 2010;37(9):1953\u201361.","journal-title":"J Rheumatol"},{"issue":"2","key":"257_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314\u201324.","journal-title":"Arthritis Rheum"},{"issue":"10019","key":"257_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671\u20138.","journal-title":"Lancet"},{"issue":"7","key":"257_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00393-006-0109-5","volume":"65","author":"F Dressler","year":"2006","unstructured":"Dressler F, Huppertz HI. Juvenile dermatomyositis. Z Rheumatol. 2006;65(7):587\u201390. 592-584","journal-title":"Z Rheumatol"},{"issue":"9 Suppl","key":"257_CR7","first-page":"S264","volume":"41","author":"HI Huppertz","year":"1998","unstructured":"Huppertz HI, Frosch M, Kuhn C, Christen HJ. Treatment of juvenile dermatomyositis (JDM) with highdose oral steroids or with steroid pulse therapy. Arthritis Rheum. 1998;41(9 Suppl):S264.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"257_CR8","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/art.24571","volume":"60","author":"S Kim","year":"2009","unstructured":"Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60(6):1825\u201330.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"257_CR9","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1136\/ard.2011.153718","volume":"70","author":"CG Lam","year":"2011","unstructured":"Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(12):2089\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"257_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.23341","volume":"59","author":"KA Rouster-Stevens","year":"2008","unstructured":"Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;59(2):222\u20136.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"257_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/acr.22198","volume":"66","author":"KA Rouster-Stevens","year":"2014","unstructured":"Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2014;66(5):783\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"257_CR12","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/acr.20269","volume":"62","author":"KA Rouster-Stevens","year":"2010","unstructured":"Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1446\u201351.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"257_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/rheumatology\/keh082","volume":"43","author":"P Riley","year":"2004","unstructured":"Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43(4):491\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"257_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/nrrheum.2011.139","volume":"7","author":"AB Robinson","year":"2011","unstructured":"Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7(11):664\u201375.","journal-title":"Nat Rev Rheumatol"},{"key":"257_CR15","unstructured":"Bundesausschuss G. Arzneimittel-Richtlinie\/ Anlage VI: Off-Label-Use Intraven\u00f6se Immunglobuline (IVIG) bei Polymyositis und bei Dermatomyositis. Bundesanzeiger. 2013. \n                    https:\/\/www.g-ba.de\/informationen\/beschluesse\/1701\/\n                    \n                  ."},{"issue":"2","key":"257_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"FB Enders","year":"2017","unstructured":"Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"257_CR17","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/acr.20695","volume":"64","author":"AM Huber","year":"2012","unstructured":"Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second childhood arthritis and rheumatology research alliance consensus conference. Arthritis Care Res (Hoboken). 2012;64(4):546\u201353.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"257_CR18","doi-asserted-by":"crossref","unstructured":"Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, Emery H, Wallace C, Grevich S, Nanda K, Zhao YD, Shenoi S, Tarvin S, Hong S, Lindsley C, Weiss JE, Passo M, Ede K, Brown A, Ardalan K, Bernal W, Stoll ML, Lang B, Carrasco R, Agaiar C, Feller L, Bukulmez H, Vehe R, Kim H, Schmeling H, Gerstbacher D, Hoeltzel M, Eberhard B, Sundel R, Kim S, Huber AM, Patwardhan A. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol. 2017;15(1).","DOI":"10.1186\/s12969-017-0174-0"},{"key":"257_CR19","volume-title":"Current management of juvenile dermatomyositis in Germany: an online survey of pediatric rheumatologists and pediatric neurologists in Germany","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Speth F, Oommen PT, Haas J-P: Current management of juvenile dermatomyositis in Germany: an online survey of pediatric rheumatologists and pediatric neurologists in Germany. 2018."},{"issue":"6","key":"257_CR20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF van Vollenhoven","year":"2014","unstructured":"van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, Aringer M, Bootsma H, Boumpas D, Bruce IN, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958\u201367.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"257_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","volume":"76","author":"U Kiltz","year":"2017","unstructured":"Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76(4):632\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"257_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 73","key":"257_CR23","first-page":"S157","volume":"30","author":"A Consolaro","year":"2012","unstructured":"Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S157\u201362.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"257_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2014.212","volume":"11","author":"C Hinze","year":"2015","unstructured":"Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol. 2015;11(5):290\u2013300.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"257_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, Rieber N, Hufnagel M, Jansson AF, Hedrich C, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J. 2018;16(1):7.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"257_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12969-017-0206-9","volume":"15","author":"G Horneff","year":"2017","unstructured":"Horneff G, Klein A, Ganser G, Sailer-Hock M, Gunther A, Foeldvari I, Weller-Heinemann F. Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2017;15(1):78.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"257_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","volume":"77","author":"JB Lilleker","year":"2018","unstructured":"Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Oakley P, Benveniste O, Danieli MG, Danko K, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77(1):30\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"257_CR28","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/rheumatology\/kel099","volume":"45","author":"LJ McCann","year":"2006","unstructured":"McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, Pilkington CA, Juvenile Dermatomyositis Research G. The juvenile dermatomyositis National Registry and repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006;45(10):1255\u201360.","journal-title":"Rheumatology (Oxford)"},{"key":"257_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13063-015-0784-0","volume":"16","author":"LJ McCann","year":"2015","unstructured":"McCann LJ, Kirkham JJ, Wedderburn LR, Pilkington C, Huber AM, Ravelli A, Appelbe D, Williamson PR, Beresford MW. Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. Trials. 2015;16:268.","journal-title":"Trials"},{"issue":"12","key":"257_CR30","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/rheumatology\/keg403","volume":"42","author":"N Ruperto","year":"2003","unstructured":"Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, Garay S, Kuis W, Machado C, Pachman L, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford). 2003;42(12):1452\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"257_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/acr.20015","volume":"62","author":"A Ravelli","year":"2010","unstructured":"Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, Maillard S, Oliveira SK, Sztajnbok F, Cuttica R, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63\u201372.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"257_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-3476(64)80325-5","volume":"64","author":"S Bitnum","year":"1964","unstructured":"Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr. 1964;64:101\u201331.","journal-title":"J Pediatr"},{"issue":"6","key":"257_CR33","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0022-3476(83)80706-9","volume":"103","author":"SL Bowyer","year":"1983","unstructured":"Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103(6):882\u20138.","journal-title":"J Pediatr"},{"issue":"2","key":"257_CR34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/art.1780250203","volume":"25","author":"WE Crowe","year":"1982","unstructured":"Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum. 1982;25(2):126\u201339.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"257_CR35","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/art.40060","volume":"69","author":"LG Rider","year":"2017","unstructured":"Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, et al. 2016 American College of Rheumatology\/European league against rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: an international myositis assessment and clinical studies group\/Paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol. 2017;69(5):911\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"257_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","volume":"47","author":"H Gunawardena","year":"2008","unstructured":"Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, Davidson JE, Cooper RG, McHugh NJ. Clinical associations of autoantibodies to a p155\/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford). 2008;47(3):324\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"257_CR37","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/acr.23113","volume":"69","author":"T Kishi","year":"2017","unstructured":"Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, et al. Association of Anti-3-Hydroxy-3-Methylglutaryl-coenzyme a reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res (Hoboken). 2017;69(7):1088\u201394.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"257_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/joim.12444","volume":"280","author":"LG Rider","year":"2016","unstructured":"Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280(1):24\u201338.","journal-title":"J Intern Med"},{"issue":"4","key":"257_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","volume":"92","author":"LG Rider","year":"2013","unstructured":"Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW, Childhood Myositis Heterogeneity Collaborative Study G. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223\u201343.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"257_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","volume":"75","author":"MA Stoffer","year":"2016","unstructured":"Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75(1):16\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"257_CR41","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","volume":"72","author":"D Lazarevic","year":"2013","unstructured":"Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013;72(5):686\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"257_CR42","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/art.21291","volume":"52","author":"CV Oddis","year":"2005","unstructured":"Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW, International Myositis A, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52(9):2607\u201315.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"257_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrrheum.2013.140","volume":"10","author":"EM DeWitt","year":"2014","unstructured":"DeWitt EM, Brunner HI. The landscape of comparative effectiveness research in rheumatology. Nat Rev Rheumatol. 2014;10(1):57\u201362.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"257_CR44","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0022-3476(96)70295-0","volume":"128","author":"B Lang","year":"1996","unstructured":"Lang B, Dooley J. Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. J Pediatr. 1996;128(3):429\u201332.","journal-title":"J Pediatr"},{"issue":"3","key":"257_CR45","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/art.1780300312","volume":"30","author":"RM Laxer","year":"1987","unstructured":"Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum. 1987;30(3):328\u201334.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"257_CR46","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3899\/jrheum.160871","volume":"44","author":"SL Tansley","year":"2017","unstructured":"Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M, Warrier K, Wedderburn LR, McHugh NJ, Juvenile Dermatomyositis Research G. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J Rheumatol. 2017;44(4):488\u201392.","journal-title":"J Rheumatol"},{"issue":"5","key":"257_CR47","first-page":"787","volume":"56","author":"E Tiniakou","year":"2017","unstructured":"Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, Parks CA, Casciola-Rosen L, Christopher-Stine L, Mammen AL. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy. Rheumatology (Oxford). 2017;56(5):787\u201394.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"257_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/rheumatology\/kew386","volume":"56","author":"WC Liang","year":"2017","unstructured":"Liang WC, Uruha A, Suzuki S, Murakami N, Takeshita E, Chen WZ, Jong YJ, Endo Y, Komaki H, Fujii T, et al. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology (Oxford). 2017;56(2):287\u201393.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0257-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-018-0257-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0257-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T19:28:52Z","timestamp":1561404532000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-018-0257-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["257"],"URL":"https:\/\/doi.org\/10.1186\/s12969-018-0257-6","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"1 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The national pediatric rheumatology database was approved by the ethics committee of the Charit\u00e9 in Berlin.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Hinze has received consulting fees, speaking fees, and\/or honoraria from Novartis (less than $10,000 each). Dr. Oommen reports no potential competing interests. Dr. Dressler has received consulting fees, speaking fees, and\/or honoraria from Novartis and Pfizer (less than $10,000 each). Dr. Weller-Heinemann has received honoraria from Abbvie, Novartis and Pfizer (less than $10,000 each). Dr. Lainka has received consulting fees, speaking fees, and\/or honoraria from Novartis (less than $10,000 each) and research support from Sobi. Dr. Brunner has received consulting fees, speaking fees, and\/or honoraria from Abbvie, MSD, Novartis, Pfizer and Roche (less than $10,000 each). Dr. F\u00f6ll is a board member of the Society for Pediatric Rheumatoloy and has received honoraria from Novartis, Pfizer, Roche-Chugai and Sobi (less than $10,000 each) and research support from Novartis and Pfizer. Dr. Neudorf has received consulting fees, speaking fees, and\/or honoraria from Chugai and Philips (less than $10,000 each), and research support from Novartis. Dr. Schwarz reports no potential competing interests. Dr. Schara is president of the Gesellschaft f\u00fcr Neurop\u00e4diatrie (GNP; Society for Pediatric Neurology in Germany) and has received consulting fees, speaking fees, and\/or honoraria from PTC Therapeutics, Deutsche Myasthenie Gesellschaft (German Myasthenia Society) and benni &co (a non-profit organization benifitting patients with muscular dystrophy). Dr. Haas is the president of the Society for Pediatric Rheumatology has received research support from Novartis and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"40"}}